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EDITORIAL
Assessing Patient Accrual to Cooperative Group Lung
Cancer Trials
Why Are Rates Disappointing?
Brian E. Lally, MD,* Henry Wagner, MD,† Corey Langer, MD,‡ and Charles R. Thomas, Jr., MD§
The recent report from the Institute of Medicine on the state of the Clinical TrialsCooperative Group (CTCG) program highlighted the importance of improving the number
of high-priority trials that successfully achieve their intended accrual goal.1 The CTCG
program (Cancer Therapy Evaluation Program), sponsored by the National Cancer Institute
(NCI), is designed to promote and support clinical trials of new cancer treatments. Most of
physicians in the CTCG system who investigate clinical/translational sciences are volunteers.2
The best way to improve survival in the lung cancer patient population is through
carefully designed phase III clinical trials. Unfortunately, many phase III trials in lung
cancer, including those designated “high priority,” have failed to answer their proposed
question(s) because they closed early due to poor accrual. Although trials comparing one
chemotherapeutic regimen to another usually accrue well, trials that combine different
therapeutic modalities (i.e., surgery versus radiotherapy) often result in poor accrual; and
yet these trials pose some of the most important clinical questions. Therefore, it is important
that we identify trials a priori with a high probability of successful accrual as well as identify
modifiable factors that can enhance accrual in these trials.
When one reviews accrual information for locally advanced non-small cell lung
cancer (NSCLC) (Table 1) initiated since 1993 by the CTCGs, only one of four trials
(25%) that involved all three conventional modalities (trials investigating different
sequences of chemotherapy, radiotherapy, and surgery) completed accrual. This contrasts
with successful accrual of four of six (66%) trials that did not involve surgery but were
primarily focused on definitive radiotherapy which met their targeted accrual. In patients
with early-stage NSCLC, stage IV NSCLC (Table 2), or small cell lung cancer (Table 3),
patient accrual was accomplished on a consistent basis. Only 1 of 18 trials failed to
achieve its accrual end point and closed early.
Enhancing accrual to individual trials can involve adding resources and/or funding
to implement actions that may improve accrual (opening at multiple institutions), simpli-
fying eligibility criteria or omitting extra tests, or closing a poorly accruing study to
release resources for others. However, the intangible element in this equation remains the
scientific relevancy that a clinical trial is investigating. This is particularly germane in
locally advanced NSCLC where trials may be investigating the role of different modalities
in the treatment paradigm. In some sense, comparing one drug against another may be
relatively easier to accomplish, but the scientific importance and potential survival impact
may be less compelling.
The design of a clinical trial can have several aspects that may limit accrual. A
challenge that constantly faces investigator is the scientific end point and the statistical
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power necessary to address this question. The end point
chosen by statisticians and principal investigators may not be
the most important end point to either patients or enrolling
clinicians. Clinical trial accrual can also be negatively af-
fected if critical members of the patient care team are not
fully engaged. For example, thoracic surgeons are a critical
component in surgery-based trials. Their “buy-in” is critical
to achieving successful accrual. On the other hand, it is
TABLE 2. Clinical Trials for Early Stage and Stage IV NSCLC Patients
Study Sponsor Study Stage Arms Design Modalities Goal Status
CALGB 9633 I 2 Adjuvant 2 344 Completed
30506 I 2 Adjuvant 2 1620 Active
140503 I 1 Diff Surg 1 1297 Active
ACOSOG Z0030 I–II 1 Diff Surg 1 1000 Completed
Z4032 I 2 Surg  Brachy 2 226 Completed
ECOG 1594 IV 2 Chemo 1 1200 Completed
4599 IV 2 Chemo 1 842 Completed
8592 IIIB–IV 3 Sclerosis 1 480 Completed
SWOG 9308 IV 2 Chemo 1 432 Completed
9509 IV 2 Chemo 1 202 Completed
S0003 IV 2 Chemo 1 500 Completed
NCIC JBR-10 Ib 2 Adjuvant 2 450 Completed
BR.19 Ib–II 2 Adjuvant 2 1160 Completed
NCCTG 97-24-51 IV 2 Chemo 1 360 Closed early
NSCLC, non-small cell lung cancer; CALGB, Cancer and Leukemia Group B; ACOSOG, American College of Surgeons Oncology Group; ECOG, Eastern Cooperative
Oncology Group; SWOG, Southwest Oncology Group; NCIC, National Cancer Institute of Canada; NCCTG, North Central Cancer Treatment Group.
TABLE 3. Clinical Trials for SCLC Patients
Study Sponsor Study Stage Arms Design Modalities Goal Status
CALGB 30610 LD-SCLC 3 RT dose 2 670 Active
9235 LD-SCLC 2 Chemo 2 319 Completed
9732 ES-SCLC 2 Chemo 1 580 Completed
RTOG 0212 LD-SCLC 3 PCI 1 252 Completed
SWOG S0124 ES-SCLC 2 Chemo 1 620 Completed
ECOG 3592 ES-SCLC 2 Chemo 1 300 Completed
7593 ES-SCLC 3 Chemo 1 420 Completed
SCLC, small cell lung cancer; PCI, prophylactic cranial irradiation; RTOG, Radiation Therapy Oncology Group; ECOG, Eastern Cooperative Oncology Group; SWOG,
Southwest Oncology Group.
TABLE 1. Phase III Clinical Trials for Mostly Locally Advanced NSCLC Patients
Study Sponsor Study Stage Arms Design Modalities Goal Status
RTOG 9309 IIIA 2 Induction 3 510 Completed
9410 II–IIIA/B 3 Definitive 2 597 Completed
9801 II–IIIA/B 2 Definitive 2 244 Completed
9701 IIIA/IIIB 2 Adjuvant 2 316 Closed early
0214 IIIA/IIIb 2 PCI 1 1058 Closed early
0412 IIA 2 Induction 3 574 Closed early
0617 IIIA/IIIB 4 Definitive 2 500 Active
ECOG E3590 II–IIIA 2 Adjuvant 3 500 Closed early
E2597 IIIA/B 2 Definitive 2 338 Closed early
E3598 IIIA/B 2 Definitive 2 588 Closed early
E1505 Ib–IIIA 2 Adjuvant 2 1500 Active
SWOG S9900 Ib–IIIA 2 Induction 2 600 Closed early
S0023 III 2 Definitive 2 840 Completed
CALGB 9734 IIIA 2 Adjuvant 3 480 Closed early
39801 IIIA/B 2 Definitive 2 360 Completed
NSCLC, non-small cell lung cancer; PCI, prophylactic cranial irradiation; RTOG, Radiation Therapy Oncology Group; ECOG, Eastern Cooperative Oncology Group; SWOG, Southwest
Oncology Group; CALGB, Cancer and Leukemia Group B.
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impossible to deny that, at times, successful accrual depends
just as much on multiple investigators who contribute but one
to two patients per year apiece. This “penny approach” to
accrual goals is reached when all the pennies add up. With
increasing pressure on investigators to avoid opening trials
that are destined to accrue poorly, this approach is becoming
more and more difficult. However, the “penny approach” may
be the most clinically relevant to the practice of oncology
throughout the entire United States.
Currently, there are strong incentives in many NCI-
designated cancer centers for investigator initiated “transla-
tional” trials which has led to an explosion of phase I–II
studies, most of which never proceed to phase III. The overall
success of clinical trial accrual through the CTCG mechanism
is thus hampered. These centers are not necessarily to blame,
particularly when their own viability depends on the conduct
of such protocols, but their agenda must be integrated into an
overall solution to rectify poor clinical trial accrual.
During protocol development, a CTCG will usually
poll its membership to document that a clinical trial concept
has equipoise/interest; accurate indices that can predict suc-
cess/failure simply do not exist. Many other factors may have
a negative effect on clinical trial accrual. Of great concern are
the large number of industry-sponsored trials which fre-
quently siphon patients from CTCG trials and which usually
offer much higher reimbursement rates. This criticism does
mean that these trials do not have less than optimal scientific
merit; but they usually focus on different drug combinations
and do not seek to optimize the integration of different
modalities. Simply, they do not ask probing questions for
which the pharmaceutical industry has no vested interest.
This is particularly acute as we witness a major drug shortage
in generic cytotoxic agents where the “profit margin” is too
slim.3 The lack of governmental regulations has placed pa-
tients’ lives at risk.
Meropol et al4 identified a lack of trust in the medical
establishment and a fear of being used as a “guinea pig for
research” as a major patient barrier to clinical trial enrollment
by oncologists. This highlights another potential means to
improve accrual by incentivizing patients. In nononcology
clinical trials, patient are commonly reimbursed a nominal
fee for their participation. Besides intensive patient and
family education to dispel misimpressions, budgeting specific
“government incentives” to reimburse patient copayments for
medical care may be a very cost-effective solution. Given the
vast amount of funding involved in clinical trials for oncol-
ogy, this should not be too difficult.
Other problems that are barriers for clinicians to par-
ticipate in clinical trials are (1) financial remuneration maybe
inadequate for each patient enrolled and (2) the trial may not
have been designed by or critiqued by the treating clinician;
hence, some clinicians lack a vested interest. This only
emphasizes how important clinician equipoise and interest
are in determining the potential success of clinical trial
accrual. To increase awareness of clinical trials, particularly
high-priority trials, the cooperative groups have employed
various tools,5 such as videotapes and slide presentations by
principal investigators, to reach out to eligible institutions and
investigators. It may be critical to have a member of the
appropriate modality lead or colead a clinical trial that inves-
tigates a particular question.
In conclusion, clinical trials investigating multimodal-
ity therapy for NSCLC have been particularly difficult to
complete, but these trials are also among the most important
when it comes to improving survival in NSCLC. The leaders
of the CTCGs, the NCI, and Cancer Therapy Evaluation
Program need to understand that the difficulty in completing
a trial should not be considered a negative but a reflection of
urgent and unmet needs of clinical research.
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